04/03/2026 - Events
On February 26 and 27, the III Meeting of the Scientific Committee of the CORDELIA project was held at the headquarters of the Fundació IMIM - Hospital del Mar Research Institute, at the Barcelona Biomedical Research Park (PRBB). This collaborative initiative integrates 35 Spanish cohorts and brings together data from 197,000 participants, with an average follow-up of more than 15 years, and has already completed three years of development.
Més informació "CORDELIA Project: advancing genetic prediction of cardiovascular disease"
03/03/2026 - Press release
They are part of the sixty research grants awarded by the organization, with total funding of more than thirteen million euros. The Spanish Association Against Cancer has awarded three of its research grants to projects led by researchers from the Hospital del Mar Research Institute (HMRIB). In total, sixty grants have been awarded: 54 to research projects and six accreditations to research centers. Altogether, this represents an investment in research of more than thirteen million euros.
27/02/2026 - Press release
High levels of this protein, which is part of blood cholesterol, are associated with a 40% higher probability of multivessel coronary atherosclerosis, directly linked to the risk of heart attack or other cardiac events. The findings come from a study led by researchers at the Hospital del Mar Research Institute and published in the American Journal of Preventive Cardiology. The authors advocate measuring lipoprotein(a) levels in all patients, not only those at high cardiovascular risk. This can be done through a simple blood test.
26/02/2026 - Press release
The Faculty Board elected him on February 10, and he officially took office on February 25. Dr. Joan Ramon Masclans, Head of the Intensive Care Medicine Department at Hospital del Mar, Coordinator of the Critical Care Pathology Research Group at the Hospital del Mar Research Institute, and Director of Teaching at the hospital, has once again been elected Dean of the Faculty of Medicine and Life Sciences at Universitat Pompeu Fabra. He will serve in the position for the next six years
19/02/2026 - Institutional news
The Hospital del Mar Research Institute (HMRIB) has appointed Judit Cubedo Ràfols as the new Managing Director of the institution. She took up the position on February 16. Judit Cubedo holds a PhD in Molecular and Cellular Biology and has a solid professional background combining scientific experience, strategic management, and health innovation. Throughout her career, she has held senior executive roles in biomedical organizations, leading institutional strategies, financial management, national and international competitive funding acquisition, technology transfer, and public-private partnerships.
Més informació "Judit Cubedo, new Managing Director of the Hospital del Mar Research Institute"
18/02/2026 - Press release
A European macro-study, published in The Lancet Regional Health-Europe, analyzes disease trajectories, associated conditions, and survival among people with cancer. Hospital del Mar and the Hospital del Mar Research Institute took part in the research, which evaluates real-world clinical data from a cohort of more than 1.7 million patients from eight European countries. The most frequent cancers in Europe are breast, prostate, colorectal, and lung cancer. The highest survival rates a re seen in breast and prostate cancer, while pancreatic cancer has the poorest prognosis. Databases from Spain, Estonia, and Switzerland show the best survival rates.
Més informació "A large-scale study analyzes the evolution of the most common cancers in Europe"
17/02/2026 - General information
The Spanish Association for Metastatic Breast Cancer (AECMM) has decided to grant one of the awards in the seventh edition of the M. Chiara Giorgetti Award for research into metastatic breast cancer to a project led by Dr. Toni Celià-Terrassa, a researcher in the Cancer Stem Cells and Metastasis Dynamics Research Group at the Hospital del Mar Research Institute. The project has received the second prize, endowed with €80,000. The award ceremony will take place next June. The project will build on the findings of a recent study by the same research group, published in the journal Cancer Cell. It will analyze the role of the protein TIM-3 in the development of resistance to neoadjuvant chemotherapy and how residual disease may serve as a predictor of metastasis. The expected results are intended to pave the way for the launch of a clinical trial led by the Medical Oncology Department at Hospital del Mar.
11/02/2026 - Institutional news
On 6 February, the XV Winter Olympic Games officially began. This year, the Games are being held in Milan-Cortina, Italy. This is a top-level sporting event that brings together athletes from around the world and mobilises numerous professionals across different fields, including anti-doping control. In this context, four professionals from the Catalonia Anti-Doping Laboratory - Rosa Ventura, Rosalia Ramírez, Deamelys Hernández and Manfred Conjeaud - will travel to Rome to join the Olympic laboratory team responsible for doping controls during the competition. Rosa Ventura will join the management and supervision group overseeing analytical activities, while Rosalia Ramírez, Deamelys Hernández and Manfred Conjeaud will work in the detection of anabolic steroids, one of the key analytical areas in sports anti-doping control.
11/02/2026 - General information
Today, 11 February, the Hospital del Mar Research Institute joins the celebration of the International Day of Women and Girls in Science, a key date to recognize the fundamental role of women in research and to continue moving towards a more just, diverse, and inclusive science. Despite the progress made, women remain underrepresented in science worldwide: less than one third of all researchers are women. At the Hospital del Mar Research Institute, every day we help advance science, medicine, and health. We are professionals from many different fields who research, care, create, and transform to expand knowledge and improve people's lives.
Més informació "The future of science begins with today's girls"
09/02/2026 - General information
The use of a standardized protocol significantly reduces headache after lumbar puncture, one of the most common side effects of this procedure, based on the analysis of more than 1,100 punctures. Improving the tolerability of lumbar puncture is key to advancing research in the preclinical stages of Alzheimer's disease and has been made possible thanks to the commitment of volunteers from the ALFA cohort. The study, published in Nature Scientific Reports, involved 724 cognitively healthy adults from the longitudinal ALFA cohort at the BBRC, with the support of the "la Caixa" Foundation.
Servei de Comunicació:
Marta Calsina(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
